Mind + Muscle

technical minds + legal muscle


dig deep

Post-Grant Review May Impact Biosimilars Litigation

  • 11.17.14
  • Marsha Rose Gillentine
  • IP Law360

Marsha Rose Gillentine, Ph.D. and Rebecca Hammond recently authored an article for IP Law360 discussing post-grant review proceedings and how they may impact biosimilars litigation. The authors suggest that these proceedings could become a forum for companies not wishing to wait until filing their biosimilars applications to challenge the validity of relevant patents.

Dr. Gillentine and Ms. Hammond suggest that biosimilar applicants who pursue a post-grant review strategy will likely challenge a secondary patent filing, such as formulation, methods of use, or methods of manufacturing, rather than a patent directed to the drug molecule itself drug molecule itself.

To read the full article, please download the attached PDF.

Related People

Related Services

Related Industries

Sort By Media Type

Sort By Media Type
  • AlertAlert
  • BriefsBriefs
  • Comments to USPTOComments to USPTO
  • Design Patent Case DigestDesign Patent Case Digest
  • MultimediaMultimedia
  • News & ArticlesNews & Articles
  • Press ReleasePress Release
  • VideoVideo
  • WebinarWebinar

Unsolicited e-mails and information sent to Sterne, Kessler, Goldstein & Fox P.L.L.C. will not be considered confidential or privileged, may be disclosed to others, may not receive a response, and do not create an attorney-client relationship with Sterne Kessler.  If you are not already a client of Sterne Kessler, do not include any confidential information in this message.